Invex Financial Statements From 2010 to 2024

Stocks . Australia . 
Stock . Invex Therapeutics
IXC Stock   0.07  0.01  7.46%   
Invex Therapeutics financial statements provide useful quarterly and yearly information to potential Invex Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Invex Therapeutics financial statements helps investors assess Invex Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Invex Therapeutics' valuation are summarized below:
Gross Profit
459.1 K
Profit Margin
(1.35)
Market Capitalization
5.4 M
Revenue
1.2 M
Earnings Share
(0.02)
There are currently fifty-four fundamental trends for Invex Therapeutics that can be evaluated and compared over time across competitors. All traders should confirm Invex Therapeutics' regular fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction.

Invex Therapeutics Total Revenue

1.27 Million

Check Invex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Invex Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 3.8 M or Interest Expense of 96.5 K, as well as many indicators such as . Invex financial statements analysis is a perfect complement when working with Invex Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Invex Therapeutics Technical models . Check out the analysis of Invex Therapeutics Correlation against competitors.

Invex Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.8 M6.1 M15.6 M
Pretty Stable
Total Current Liabilities410 K431.6 K967.4 K
Very volatile
Total Stockholder Equity5.4 M5.7 M14.7 M
Pretty Stable
Net Tangible Assets26.5 M32.8 M18.3 M
Slightly volatile
Accounts Payable5.3 K5.6 K650.3 K
Slightly volatile
Cash5.7 M6 M15.5 M
Pretty Stable
Other Assets0.80.90.98
Slightly volatile
Cash And Short Term Investments5.7 M6 M15.5 M
Pretty Stable
Net Receivables146.3 K95 K108.6 K
Slightly volatile
Common Stock Shares Outstanding69.8 M75.3 M42.6 M
Slightly volatile
Liabilities And Stockholders Equity5.8 M6.1 M15.6 M
Pretty Stable
Other Current Assets146.3 K95 K108.6 K
Slightly volatile
Total Liabilities410 K431.6 K967.4 K
Very volatile
Total Current Assets5.8 M6.1 M15.6 M
Pretty Stable
Common Stock31.2 M22.4 M19.7 M
Slightly volatile
Other Current Liabilities696.5 K426 K1.5 M
Slightly volatile
Common Stock Total Equity21.6 M24.3 M26.5 M
Slightly volatile
Net Invested Capital5.4 M5.7 M22.5 M
Slightly volatile
Capital Stock25.4 M22.4 M28.5 M
Pretty Stable
Net Working Capital5.4 M5.7 M22.5 M
Slightly volatile

Invex Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.8 M2.1 M1.8 M
Slightly volatile
Selling General Administrative1.1 M1.2 M574.1 K
Slightly volatile
Selling And Marketing Expenses91.8 K158.1 K71 K
Slightly volatile
Total Revenue1.3 M1.2 M230.1 K
Slightly volatile
Gross Profit1.3 M1.2 M233 K
Slightly volatile
Other Operating Expenses4.2 M3.3 M1.9 M
Slightly volatile
Research Development2.8 M2 M1.2 M
Slightly volatile
Total Operating Expenses4.2 M3.3 M1.9 M
Slightly volatile
Net Interest Income372.5 K491.8 K237.1 K
Slightly volatile
Interest Income372.5 K491.8 K237.1 K
Slightly volatile

Invex Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow5.7 M6 M15.5 M
Pretty Stable
Change To Netincome622.1 K319.8 K878.1 K
Slightly volatile
Stock Based Compensation130.6 K137.5 K766.5 K
Slightly volatile
Issuance Of Capital Stock10 M7.8 M13.7 M
Slightly volatile

Invex Fundamental Market Drivers

Cash And Short Term Investments6 M

About Invex Therapeutics Financial Statements

Invex Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Invex Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Invex Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Invex Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue1.2 M1.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Invex Stock Analysis

When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY